Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of KW-6356 in Hepatic Impairment
NCT04190654Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sipagladenant in Parkinson's disease (PD) (3 arms), sponsored by Kyowa Kirin. Primary endpoints: Maximum Plasma Concentration at Day 12, Area Under the Curve from Time Zero to Last Quantifiable Concentration at Day 12 and 5 more. Started Nov 2019; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04190654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190654.